Russian biologist Denis Rebrikov has announced his intentions to produce further gene-edited babies, ignoring the scientific consensus that this should not be done until an ethical framework is constructed to regulate the science involved. Rebrikov’s plans could occur before the end of the year if he receives approval in time.
Genomics will change what patients expect from their provider, as well as change how physicians treat them. Before this happens, education on both sides is needed. This month we look at some of the big talking points.
Non-Alcoholic Steatohepatitis (NASH) is the most severe form of non-alcoholic fatty liver disease (NAFLD). The global prevalence of NAFLD is as high as one billion and is the most common cause of chronic liver disease, affecting between 80 and 100 million in the U.S., among whom nearly 25% progress to NASH. NASH is characterized by […]
As part of the Next Generation Children project at Addenbrooke’s Hospital and Cambridge University, all seriously ill children in England with unexplained disorders will be able to have their genomes analysed from 2020. The project should mean quicker diagnoses for families in the future.
Dr. Eric Kmiec, Director of the Gene Editing Institute at Christiana Care Health System, spoke at BIO 2019 about meeting unmet medical needs with gene editing. We spoke to him about his work at Christiana Care Health System and CRISPR’s role in promoting better social equality in life science.
The US government has ended medical research funding for scientists using foetal tissue, and cancelled a multi million-dollar contract for a laboratory at the University of California at San Francisco, which required the material to test new HIV therapies. According to a White House spokesperson, the decision was taken by President Trump himself.
Researchers have genetically modified stem cells inside the bodies of mice for the first time, in a study that could lead eventually to new potential for stem cell therapies. The study also shows potential for studying genetically-edited stem cells within the body, rather than in the lab.
He Jiankui, the Chinese scientist who created the first gene-edited twin children last year, could have unknowingly shortened their lives by more than 1.9 years. A study into the DNA and death records of 400,000 volunteers in the UK Biobank found the genetic mutations to gene CCR5 were “of quite strong effect.”
University of Maryland scientists have genetically modified a fungus to produce a toxin fatal to mosquitoes, in order to reduce the malaria death toll they currently cause. An out-of-lab trial destroyed a mosquito population almost entirely within 45 days, leading some to criticise the work as “too dangerous” for the real world.
Princeton University researchers have used AI techniques to uncover junk DNA mutations which can lead to autism. The findings are the first to link functionally link mutations in regulatory DNA with a disease like autism, and possibly prove that the changes affect how genes are expressed in the brain.
The FDA has cleared the most expensive drug yet, Novartis’ gene therapy drug Zolgensma, for introduction to the market. Zolgensma, created to combat spinal muscular atrophy, has been priced at $2.125 million, or $425,000 annually over five years.
GEDMatch, the DNA database which made news recently for its instrumental role in solving cold criminal cases in the US, has blocked law enforcement from accessing information for the millions of people on its system.
Cambridge University scientists have created the first living organism with fully synthetic DNA radically altered from its original state. The strain of E coli was given a smaller set of genetic instructions than its counterparts, proving life can continue with such a restricted code.
UK Biobank has released a vast tranche of genetic data to health researchers around the world, offering an unprecedented resource to enhance understanding of human biology and aid in therapeutic discovery. This follows a brief exclusive research period for Regeneron and GSK. Additional tranches of data will be released over the next two years.
Dr Ben Langmead is a computational biologist and assistant professor in the Computer Science Department at Johns Hopkins University, most famous for his creation of the Bowtie and Bowtie 2 sequence alignment algorithms, used to improve sequencing alignment quality. FLG spoke to Dr Langmead about his lab, his recent work using the Stampede2 supercomputer cluster to optimise sequencing data analysis software, and the future for DNA sequencers as a whole.
Yale University researchers have discovered a potential new biomarker for identifying individuals with increased risk of prostate cancer metastasis. The findings announced that mitochondrial protein syntaphilin is vital in determining the balance between tumour cell proliferation and tumour cell invasion, and is expressed significantly at the invasive tumour edge in prostate cancer.